# Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial

> **NCT00165048** · PHASE3 · UNKNOWN · sponsor: **Chinese University of Hong Kong** · enrollment: 206 (—)

## Conditions studied

- Cancer of Stomach

## Interventions

- **DRUG:** Vioxx (Rofecoxib)

## Key facts

- **NCT ID:** NCT00165048
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 206 (—)
- **Last updated:** 2005-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165048, "Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00165048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*